LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus ...
Investigators studied expression of type I interferons, key pathogenic drivers in systemic lupus erythematosus and lupus nephritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results